Cardiology

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.

hATTR compass program will empower people with accurate genetic information so they can make informed decisions about their healthcare.

The results suggest that this approach could streamline the diagnosis of diabetes, losing the need for the same elevated test needing to be repeated in a new blood sample.

Clinical data demonstrate that CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina.

Ray Comenzo, MD, highlights promising ANDROMEDA phase 3 trial, which evaluated the efficacy of subcutaneous daratumumab and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy for newly diagnosed light chain (AL) amyloidosis patients.

Those discharged early and administered rivaroxaban saved $2496 and spent 26.4 fewer hours hospitalized over the course of 90 days.

IgE for alpha-gal was identified in 26% of the patients, and plaque buildup was 30% higher in those patients compared to those that were not sensitized.

The 1300-plus patient survey interim results show patients struggle with fatigue and maintaining control of daily functions.

Data revealed that the 1-year patency rate was 89.1% via Kaplan Meier estimate at day 360, and a CD-TLR rate of 7.1%.

Right ventricular response to exercise may be used as a better indicator of ventricular-arterial coupling than resting hemodynamics, say authors of this new study.

Results of a new study identify specific clinical characteristics linked to poor quality of life in patients with PAH.

The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee panel voted 11-4 to support the benefits of the INCRAFT AAA Stent Graft System from Cardinal Health.

The catheter is now indicated for use with an aspiration technique for blood clot removal in patients with acute ischemic stroke.

Barton-Maxell details the importance of caring for stage A heart failure patients in the primary care setting.

Updated research regarding the ANDROMEDA study indicates the efficacy of subcutaneous daratumumab (DARA SC) and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy in newly diagnosed light chain (AL) amyloidosis patients.

The biologic was previously approved for patients with hemophilia A with factor VIII inhibitors, but additional results indicated efficacy for patient without factor VIII inhibitors as well.

There was a dose-response pattern of psychological distress associated with significantly increased risk for COPD, cardiovascular disease, and arthritis.

Methamphetamine abuse is on a steady rise in the US. A new study highlights the nature and dangers of Meth-PAH.

Those with hypertension had roughly 2.5 times more inpatient costs, almost twice the outpatient cost, and roughly triple the prescription medication cost annually.

A survey of internal medicine residents found that differing professional needs and perceptions of the field of cardiology were strongly associated with decisions to pursue or avoid cardiology careers.

Individualized holistic, evidence-based medicine will be accessible to more patients in New York beginning in June 2018, when the 2-year-old Integrative Health and Wellbeing program expands from its original site.

The cap is the first and only device that kills infection-causing bacteria inside a long-term catheter, preventing contamination.

Eltrombopag (Promacta) was granted Priority Review designation, indicating a 6-month timeline for review.

A growing class of medications, SGLT-2 inhibitors have helped physicians manage otherwise uncontrolled cases of type 2 diabetes.

This week on MDNN: Cinnamon flavoring in e-cigarettes has been found to disrupt the lungs’ anti-bacterial defense system, new hypertension guidelines have increased the condition's prevalence, and the US Congress passed a right-to-try bill.

This morning, Pfizer announced that its investigational therapy for the treatment of patients with transthyretin (TTR) cardiomyopathy, tafamidis, received Breakthrough Therapy designation from the US FDA.